Amgen vs L'Oreal: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. L'Oreal was founded in 1909 by Eugène Schueller and is led by Nicolas Hieronimus.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
L'Oreal
Eugène Schueller
L'Oréal possesses a scientific, chemical founding story, rooted not in the glamorous salons of Paris, but in the rigorous, heavily experimental laboratories of an effective young chemist desperately trying to solve a specific cosmetic problem.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
L'Oreal
- Jean-Paul Agon2006–2021
Chairman of the Board (former CEO)
Jean-Paul Agon led L'Oréal as CEO for 15 years, overseeing the company's transformation from a European beauty leader into the world's dominant global beauty company.
Source - Nicolas Hieronimus2021–present
Chief Executive Officer
Nicolas Hieronimus joined L'Oréal in 1987 and spent 30 years in brand management and divisional leadership before being named CEO in May 2021, succeeding Jean-Paul Agon.
Source
Timeline: Amgen and L'Oreal side by side
1909L'Oreal
Company Founded
Eugène Schueller registers the Société Française de Teintures Inoffensives pour Cheveux in Paris with 800 francs in capital, beginning commercial sale of his Oréale hair dye formula to Parisian hairdressers.
1912L'Oreal
First International Expansion
L'Oréal hair dyes reach distribution in the Netherlands, Austria, and Italy, establishing the international distribution ambition that would eventually span 150 countries.
1929L'Oreal
Imédia First Consumer Hair Dye
L'Oréal introduces Imédia, the world's first hair dye product formulated for home application by consumers, marking the company's pivot from purely professional B2B to consumer-facing distribution.
1963L'Oreal
Euronext Paris IPO
L'Oréal lists on the Paris Stock Exchange, providing capital for accelerated international expansion and establishing the public shareholder structure that persists today alongside the Bettencourt family's controlling stake.
1971L'Oreal
'Because You're Worth It' Campaign Launched
Copywriter Ilon Specht creates the 'Because You're Worth It' tagline for L'Oréal Paris one of the most enduring advertising phrases in consumer goods history, reframing beauty products as expressions of female self-worth rather than instruments of male approva…
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1991L'Oreal
Acquisition of La Roche-Posay
L'Oréal acquires La Roche-Posay, the French dermo-cosmetic brand founded in 1975, establishing its first significant presence in the pharmacy channel and laying groundwork for what would become the Dermatological Beauty division.
1996L'Oreal
Maybelline Acquisition
L'Oréal acquires Maybelline New York from Wasserstein Perella for approximately $758 million, instantly becoming the global leader in mass-market color cosmetics and significantly expanding its North American market position.
2000L'Oreal
Matrix and Kiehl's Acquisitions
L'Oréal acquires professional hair care brand Matrix and American apothecary brand Kiehl's Since 1851, broadening both the professional channel and the prestige specialty retail presence in the U.S. Market.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2017L'Oreal
CeraVe Acquisition $1.3 Billion
L'Oréal acquires CeraVe, AcneFree, and Ambi from Valeant Pharmaceuticals for $1.3 billion.
2018L'Oreal
ModiFace Acquisition Beauty Tech
L'Oréal acquires ModiFace, a Toronto-based augmented reality and artificial intelligence beauty technology company, establishing a proprietary virtual try-on and skin diagnostic platform deployed across brand apps, retail partner websites, and social media pla…
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2021L'Oreal
Nicolas Hieronimus Becomes CEO
Nicolas Hieronimus, a 30-year L'Oréal veteran who led the Luxe division's transformation, succeeds Jean-Paul Agon as Chief Executive Officer, bringing strategic continuity while accelerating digital commerce and sustainability investment.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023L'Oreal
Aesop Acquisition $2.5 Billion
L'Oréal completes the acquisition of Aesop, the Australian premium natural beauty brand, from Natura &Co for $2.525 billion the company's largest acquisition in over a decade and a strategic entry into the premium wellness and natural beauty segment.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025L'Oreal
FY2025 Sales Reach 44.052 Billion
LOral reported 44.052 billion in FY2025 sales, 4.0% like-for-like growth, 8.892 billion in operating profit, 6.127 billion in net profit after non-controlling interests, and more than 95,000 employees.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026L'Oreal
Kering Beauté Acquisition Completed
L'Oréal closed the ~$4.52 billion (€4 billion) purchase of Kering Beauté, including Creed, with 50-year licences for Bottega Veneta, Balenciaga and, from July 2027, Gucci.
2026L'Oreal
Record First-Half Margin
H1 2026 sales reached ~$26.9 billion (€23.77 billion), up 6.8% like-for-like, with a record 21.3% operating margin.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
L'Oreal
- Kering Beauté (including Creed)2026$4B
- Aesop2023$2.5B
- CeraVe, AcneFree, and Ambi (from Valeant Pharmaceuticals)2017$1.3B
- IT Cosmetics2016$1.2B
- Maybelline New York1996$758M
Questions about Amgen vs L'Oreal
Who is the CEO of Amgen Inc. and L'Oréal SA?
Amgen Inc. is led by Robert A. Bradway and L'Oréal SA is led by Nicolas Hieronimus. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs L'Oréal SA?
L'Oréal SA was founded in 1909 — 71 years before Amgen Inc., which was founded in 1980. L'Oréal SA's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to L'Oréal SA?
Amgen Inc. employs approximately 31,500 people, while L'Oréal SA employs approximately 95,000. L'Oréal SA has the larger workforce at 95,000 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and L'Oréal SA headquartered?
Amgen Inc. is headquartered in United States and L'Oréal SA is headquartered in France. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and L'Oréal SA?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. L'Oréal SA was founded by Eugène Schueller.
Which company has a longer operating history — Amgen Inc. or L'Oréal SA?
L'Oréal SA has been operating for approximately 117 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs L'Oreal overview